Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon α mono and combination therapy regimens

被引:55
作者
Schmid, M
Kreil, A
Jessner, W
Homoncik, M
Datz, C
Gangl, A
Ferenci, P
Peck-Radosavljevic, M
机构
[1] Univ Vienna, Dept Internal Med 4, Div Gastroenterol & Hepatol, A-1090 Vienna, Austria
[2] KH Oberndorf, Dept Internal Med, Salzburg, Austria
关键词
D O I
10.1136/gut.2004.057893
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Treatment of chronic hepatitis C with interferon (IFN)-alpha and ribavirin has haematotoxic effects. We evaluated the effects of four different IFN/IFN-ribavirin treatment regimens on haematopoiesis. Methods: Haematopoiesis was studied in 133 patients with chronic hepatitis C receiving IFN-alpha 2b alone (group A) or in combination with ribavirin (group B), pegylated IFN-alpha 2a (group C), or pegylated IFN-alpha 2b (group D) in combination with ribavirin. Results: At week 4, haemoglobin levels were diminished in all groups receiving combination therapy. In the monotherapy group, haemoglobin decreased slightly after eight weeks. In all groups, haemoglobin remained diminished throughout therapy. In all patients, leucocytes (while blood cells) decreased after four weeks and remained low during treatment. Platelets (peripheral platelet count (PPC)) were decreased in all groups after four weeks and remained below baseline levels during therapy in group A, C, and D whereas in group B PPC recovered early and reached baseline levels at week 16 of therapy. Concomitantly with the decreases in haemoglobin and PPC, erythropoietin increased in all groups receiving combination therapy and thrombopoietin in all groups. Patients treated with pegylated IFN-alpha 2a and those who received pegylated IFN-alpha 2b combination therapy differed only in leucopoiesis, whereas erythropoiesis and thrombopoiesis were comparable. Conclusion: IFN-alpha based therapies are associated with a decrease in all three haematopoietic lineages, irrespective of the type of therapy used. The stronger suppressive effect of pegylated IFN-alpha 2a on leucopoiesis could be due to a dose effect. Overall, concentrations of endogenous haematopoietic growth factors are increased but can only partially alleviate haematotoxicity. Potential uses of exogenous haematopoietic growth factors and their impact on the virological response need to be explored.
引用
收藏
页码:1014 / 1020
页数:7
相关论文
共 48 条
[1]   Epoetin alfa treatment of anemic HCV-infected patients allows for maintenance of ribavirin dose, increases hemoglobin levels, and improves quality of life vs placebo: a randomized, double-blind, multicenter study [J].
Afdhal, NH ;
Dieterich, DT ;
Pockros, PJ ;
Schiff, ER ;
Shiffman, ML ;
Sulkowski, MS ;
Wright, T ;
Younossi, Z ;
Bowers, PJ .
GASTROENTEROLOGY, 2003, 124 (04) :A714-A714
[2]   Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial [J].
Bodenheimer, HC ;
Lindsay, KL ;
Davis, GL ;
Lewis, JH ;
Thung, SN ;
Seeff, LB .
HEPATOLOGY, 1997, 26 (02) :473-477
[3]   THROMBOPOIETIN (C-MPL LIGAND) ACTS SYNERGISTICALLY WITH ERYTHROPOIETIN, STEM-CELL FACTOR, AND INTERLEUKIN-11 TO ENHANCE MURINE MEGAKARYOCYTE COLONY GROWTH AND INCREASES MEGAKARYOCYTE PLOIDY IN-VITRO [J].
BROUDY, VC ;
LIN, NL ;
KAUSHANSKY, K .
BLOOD, 1995, 85 (07) :1719-1726
[4]  
Burroughs AK, 2000, LIVER TRANSPLANT, V6, pS35, DOI 10.1053/jlts.2000.18690
[5]   Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C [J].
Davis, GL ;
Esteban-Mur, R ;
Rustgi, V ;
Hoefs, J ;
Gordon, SC ;
Trepo, C ;
Shiffman, ML ;
Zeuzem, S ;
Craxi, A ;
Ling, MH ;
Albrecht, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) :1493-1499
[6]   Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage [J].
De Franceschi, L ;
Fattovich, G ;
Turrini, F ;
Ayi, K ;
Brugnara, C ;
Manzato, F ;
Noventa, F ;
Stanzial, AM ;
Solero, P ;
Corrocher, R .
HEPATOLOGY, 2000, 31 (04) :997-1004
[7]  
DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A
[8]   Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa [J].
Dieterich, DT ;
Wasserman, R ;
Bräu, N ;
Hassanein, TI ;
Bini, EJ ;
Bowers, PJ ;
Sulkowski, MS .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (11) :2491-2499
[9]  
Dieterich DT, 2002, HEPATOLOGY, V36, p286A
[10]  
Dieterich DT, 2001, GASTROENTEROLOGY, V120, pA64